Spruce Street Funds Hold 6.4% Of Entera Bio Without Seeking To Influence Control
The investment manager reported shared voting authority over 11,213,455 ordinary shares in the clinical-stage drug developer.
Funds managed by Spruce Street Capital held a 6.4% stake in Entera Bio, which develops oral versions of therapies usually delivered by injection, as of September 30, 2026. In a passive ownership disclosure filed Friday, the reporting persons certified that the shares were held for ordinary business purposes without seeking to change or influence the company's control.
Shared Votes Over 11.2 Million Shares
Spruce Street Capital, the investment manager for the funds and accounts holding the shares, reported beneficial ownership of 11,213,455 ordinary shares. It reported shared voting authority over the entire position.
Spruce Street Capital Master Fund, one of those funds, has rights to receive dividends or direct dividend payments and sale proceeds associated with more than 5% of Entera's outstanding ordinary shares. The disclosure concerns shares held by the managed funds and accounts.
The 6.4% calculation used Entera's previously reported share base: 173,922,428 ordinary shares outstanding on September 18, 2026. Entera supplied that figure in a preliminary proxy statement filed September 23, 2026.
Tablets For Typically Injected Therapies
Entera is a clinical-stage drug developer with no approved products. Its N-Tab technology aims to shield large peptides from the digestive tract and help them reach the bloodstream.
EB613, an oral teriparatide treatment for osteoporosis, is its most advanced drug candidate. Entera holds global rights to that program.
Its other candidates include EB612, an oral parathyroid hormone treatment for hypoparathyroidism, and an oral GLP-2 treatment for short bowel syndrome. Entera is also developing an oral GLP-1/Glucagon candidate for obesity and metabolic disorders.
OPKO Shares The Development Effort
Several Entera programs involve OPKO Biologics, a subsidiary of OPKO Health. In the oral GLP-1/Glucagon program, Entera retains 40% of proceeds and OPKO retains 60%.
Entera's market capitalization was $561 million as of 4:10 p.m. ET Friday. The ownership percentage in Spruce Street's disclosure measures the funds' position against the earlier ordinary-share count.